



CHEMICAL BIOLOGICAL MEDICAL SYSTEMS



Presented to:
***Quarterly Chemical/Biological Executive
Roundtable Breakfast***

Presented by:
COL Stephen B. Berté
Joint Project Manager, CBMS
301-619-7400
stephen.berte@us.army.mil

September 25, 2003



CBMS Mission



**The Chemical Biological Medical Systems
Joint Project Management Office (CBMS)
develops, procures, fields, and sustains
premier medical protection and treatment
capabilities against chemical and
biological warfare agents.**



CBMS Integrated Products



PREVENTION



Prophylaxis preserves force

DETECTION



Treatment preserves life

DIAGNOSIS TREATMENT





Medical Identification & Treatment Systems



MIT S manages the development and acquisition of safe, effective, and FDA-approved products used for prophylaxis, treatment, and diagnosis of chemical and biological warfare agent exposure.





Chemical Defense Medical Products



FDA Approved

- **M291 Skin Decontaminating Kit**
- **Reactive Skin Decontamination Lotion (RSDL)**
- **Convulsant Antidote Nerve Agent (CANNA)**
- **Medical Aerosolized Nerve Agent Antidote (MANAA)**
- **Sodium Thiosulfate for Cyanide Poison**
- **Skin Exposure Reduction Paste Against Chemical Warfare Agents (SERPACWA)**



Chemical Defense Medical Products (*cont.*)



FDA Approved (cont'd)

- Antidote Treatment, Nerve Agent Autoinjector (ATNAA)
- Soman Nerve Agent Pretreatment Pyridostigmine (SNAPP)




Chemical Defense Medical Products (cont.)



In Development

- **Advanced Anticonvulsant System (AAS)**

Business Opportunity:



Lead integrating contractor to manufacture the AAS. Have drug and own rights to auto-injector delivery system. \$1M over FY04-07.

- **Next Generation Oxime**
- **BioScavenger – Human Butrylcholinesterase**



Joint Biological Agent Identification & Diagnostic System (JBAIDS)



- **Polymerase Chain Reaction (PCR) platform for Biological Warfare Agent (BWA) detection and diagnosis (FDA)**
- **Reusable, portable, modifiable system**
- **Simultaneous reliable ID of multiple BWAs and other pathogens**
- **Identification \leq 60 Mins**



JBAIDS Acquisition Strategy




- **Evolutionary**

- ***Block I: Portable detector***

- **Block II: (Currently unfunded)**

- **FDA approved diagnostics**

- **Remote database access**



Business Opportunities (FY07?):

Reduction in size/weight; sample automation; remote database access



JBAIDS Acquisition Strategy



- **Evolutionary (cont'd)**

- FY08? Unfunded


- Block III:

- Hand held

- Automated and integrated system

- New diagnostic capabilities

- New diagnostic technologies





Critical Reagents Program



- Provides high quality antigen-antibody and PCR reagents
- Supports variety of BWA detector & diagnostic platforms
- Standardizes procedures and training
- Optimizes and transitions technologies to the field



CHEMICAL BIOLOGICAL MEDICAL SYSTEMS



COL Stephen B. Berté

Joint Project Manager, CBMS

301-619-7400

stephen.berte@us.army.mil